BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBIO BridgeBio Pharma, Inc.

盘前交易 10-19 07:27:20 EDT

66.39

-0.74

-1.10%

盘前66.50

+0.11+0.17%

07:14 EDT

最高67.04	最低65.26	成交量205.56万
今开67.03	昨收67.13	日振幅2.65%
总市值130.00亿	流通市值110.87亿	总股本1.96亿
成交额1.36亿	换手率1.23%	流通股本1.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":66.39,"timestamp":1792180800000,"preClose":67.13,"halted":0,"volume":2055584,"hourTrading":{"tag":"盘前","latestPrice":66.5,"preClose":66.39,"latestTime":"07:14 EDT","volume":21,"amount":1396.5,"timestamp":1792408487010,"change":0.11,"changeRate":0.001657,"amplitude":0},"delay":0,"changeRate":-0.011023387457172575,"floatShares":167000000,"shares":195806242,"eps":-3.5686,"marketStatus":"盘前交易","change":-0.74,"latestTime":"10-19 07:27:20 EDT","open":67.03,"high":67.04,"low":65.26,"amount":136150578.44799998,"amplitude":0.026516,"askPrice":67.49,"askSize":17,"bidPrice":65.51,"bidSize":17,"shortable":3,"etf":0,"ttmEps":-3.5686,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792416600000},"marketStatusCode":1,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":66.39,"preHourTrading":{"tag":"盘前","latestPrice":66.5,"preClose":66.39,"latestTime":"07:14 EDT","volume":21,"amount":1396.5,"timestamp":1792408487010,"change":0.11,"changeRate":0.001657,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":66.35,"preClose":66.39,"latestTime":"19:41 EDT","volume":14227,"amount":944497.85,"timestamp":1792194094327,"change":-0.04,"changeRate":-0.000603,"amplitude":0.000603},"volumeRatio":0.8803368157762071,"impliedVol":0.5254,"impliedVolPercentile":0.496},"requestUrl":"/m/hq/s/BBIO","defaultTab":"news","newsList":[{"id":"2669437918","title":"BridgeBio(BBIO.US)心脏病疗法acoramidis真实世界研究表现优于辉瑞(PFE.US)竞品药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437918","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669437918?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:32","pubTimestamp":1790209969,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4568","LU0170899867.USD","IE00B19Z3581.USD","SG9999001176.USD","IE0002270589.USD","SG9999002224.SGD","BK4588","BK4533","BK4139","SG9999013999.USD","LU0058720904.USD","IE00BBT3K403.USD","OZEM","LU0234572021.USD","IE00BLSP4239.USD","LU0321505868.SGD","BK4550","LU0985481810.HKD","LU1883839398.USD","SG9999001176.SGD","LU1894683264.USD","LU0122379950.USD","LU0306806265.USD","BK4505","LU0225284248.USD","LU2596442595.SGD","LU0321505439.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","BK4007","LU0456855351.SGD","LU0289739699.SGD","LU0225771236.USD","LU0306807586.USD","BK4534","SGXZ57979304.SGD","LU1057294990.SGD","LU1066053197.SGD","BK4592","SG9999011175.SGD","PFE","BK4585","IE00BLSP4452.SGD","SG9999003800.SGD","BBIO","IE00B3T34201.USD","LU0868494617.USD","LU1066051498.USD","LU1894683348.USD","SG9999002232.USD","IE000M9KFDE8.USD","BK4581","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155333489","title":"BridgeBio Pharma：口服Infigratinib在52周睡眠呼吸暂停与中耳炎研究中展现优于安慰剂的积极趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1155333489","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155333489?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:06","pubTimestamp":1788941169,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma近日披露，其口服药物Infigratinib在为期52周的临床试验中，针对睡眠呼吸暂停和中耳炎两大适应症，呈现出相较于安慰剂更为有利的疗效趋势。这一阶段性成果为该候选药物的后续开发注入了信心，也引发了市场对该公司在呼吸及耳鼻喉领域布局的重新审视。尽管数据尚未达到统计学显著性差异，但所展现出的临床信号仍值得关注。分析人士指出，Infigratinib作为一种成纤维细胞生长因子受体（FGFR）抑制剂，其作用机制或在此类非肿瘤适应症中开辟新的应用路径。公司方面表示，将持续推进相关临床项目，并期待在后续更大规模研究中进一步验证该疗法的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","BBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112994856","title":"BridgeBio Pharma向FDA提交口服Infigratinib治疗软骨发育不全的新药申请，预计2027年年中在美国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1112994856","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112994856?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:01","pubTimestamp":1788940869,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.宣布，已向美国食品药品监督管理局（FDA）提交了口服Infigratinib用于治疗软骨发育不全的新药申请（NDA）。该公司预计该药物将于2027年年中在美国市场推出。这一举措标志着公司在推进这一潜在疗法方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BBIO","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121614834","title":"口服Infigratinib在III期Propel 3试验中展现软骨发育不全患儿52周内生长之外的显著疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1121614834","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121614834?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:00","pubTimestamp":1788940812,"startTime":"0","endTime":"0","summary":"口服Infigratinib在针对软骨发育不全患儿的III期Propel 3试验中，于52周治疗窗口内展现出超越单纯生长指标的实质性获益。这一发现为罕见骨骼发育疾病领域带来了新的治疗曙光。研究数据显示，该药物不仅促进了患儿的线性生长，还在多个功能性和临床相关终点上呈现出积极改善。这些结果进一步巩固了Infigratinib作为潜在疾病修饰疗法的科学基础，并为其后续临床开发提供了有力支撑。试验所揭示的疗效广度，或将对患儿的生活质量及长期骨骼健康产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","BBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193919666","title":"BridgeBio宣布Ascend-Attr研究完成首例患者给药，该3B/4期临床试验评估Acoramidis对ATTR-CM疾病逆转的长期疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1193919666","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193919666?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:33","pubTimestamp":1787744020,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma宣布，其Ascend-Attr研究项目已完成首位参与者的药物给药。这项3B/4期临床试验旨在深入评估Acoramidis在转甲状腺素蛋白淀粉样变性心肌病治疗中对疾病逆转进程的长期影响。Acoramidis作为一种在研药物，其潜在的疾病修饰能力备受关注——它能否真正推动ATTR-CM的病情逆转，正是这项研究希望解答的核心问题。业界对这一研究结果抱有期待——若数据积极，Acoramidis或将为这类患者群体带来全新的治疗选择，重塑现有的临床管理格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4139","BK4588","BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659418831","title":"BridgeBio（BBIO）二次发行 确定每股78美元折价出售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2659418831","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659418831?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:19","pubTimestamp":1786709990,"startTime":"0","endTime":"0","summary":"出让500万股普通股，发行最终定价确定为每股78美元，公司主体并不参与股份出售，也不会从本次二次发行当中取得资金收益。对比前一交易日的市场价格可以看到，BBIO在2026年8月13日收盘报价为每股81.21美元，78美元的发行价较收盘价折价3.21美元，折价幅度大约4%。市场后续将关注股份解禁流通之后，二级市场筹码供给变化对 BBIO短期股价带来的扰动。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303815","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","UDN","BBIO","BK4139","BK4588","UUP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197251649","title":"BridgeBio Pharma公布KKR Genetic Disorder L.P. 500万股二次发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1197251649","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197251649?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:31","pubTimestamp":1786707093,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.宣布，已由KKR Genetic Disorder L.P.对其500万股普通股进行了二次发行定价。此次发行定价已正式公布，标志着该交易进入关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BBIO","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133543220","title":"BridgeBio Pharma宣布启动由现有股东发起的普通股二次发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1133543220","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133543220?lang=zh_cn&edition=full","pubTime":"2026-08-14 05:44","pubTimestamp":1786657454,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.正式对外宣布，将代表一位现有股东启动一项普通股的二次发行计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO","BK4139","BK4585","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196589136","title":"BridgeBio Pharma 提交文件：股东拟出售最多2460万股普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1196589136","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196589136?lang=zh_cn&edition=full","pubTime":"2026-07-25 05:23","pubTimestamp":1784928232,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 已向美国证券交易委员会（SEC）提交文件，计划由售股股东进行最高达2460万股普通股的公开发售。这一动态源自公司最新的监管申报文件，凸显了现有股东的减持意图。市场参与者正密切关注此次大规模股票供应对股价的潜在影响。截至目前，BridgeBio尚未明确本次发售的具体时间表或定价细节，后续进展值得投资者持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BBIO","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134873174","title":"BridgeBio Pharma旗下Encaleret治疗ADH1的三期CALIBRATE试验达到所有主要及关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1134873174","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134873174?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:31","pubTimestamp":1784719873,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 宣布，其用于治疗常染色体显性低钙血症1型（ADH1）的在研药物encaleret，在三期CALIBRATE试验中成功达成了所有预设的主要终点与关键次要终点。这一积极结果标志着该疗法在应对这一罕见遗传性疾病方面取得了关键性进展，为后续向监管机构提交申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BBIO","BK4505","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150926961","title":"异动解读｜BridgeBio Pharma盘中下跌5.02%，报85.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150926961","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150926961?lang=zh_cn&edition=full","pubTime":"2026-07-11 02:45","pubTimestamp":1783709129,"startTime":"0","endTime":"0","summary":"7月11日，BridgeBio Pharma盘中下跌5.02%，报85.64美元/股，成交额3.29亿美元。BridgeBio Pharma所在的生物科技行业中，个股普遍承压，其中艾伯维公司跌1.1%，阿尔尼拉姆制药公司跌4.01%，Ionis Pharmaceuticals跌8.54%，Moderna跌10.84%，吉利德科学跌3.66%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192236506","title":"异动解读｜BridgeBio Pharma盘中上涨10.17%，10亿美元私募融资加速多款罕见病新药商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1192236506","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192236506?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:43","pubTimestamp":1783604626,"startTime":"0","endTime":"0","summary":"7月9日，BridgeBio Pharma盘中上涨10.17%，报90.57美元/股，成交额2.11亿美元。消息面上，私募资本KKR与Sixth Street Partners已同意向公司提供10亿美元优先股融资，其中Sixth Street领投约8亿美元，初始转换价为每股138美元，较30日均价溢价100%。资金将用于加速三款罕见病核心管线BBP-418、encaleret及infigratinib的商业化推进。其中BBP-418已获FDA优先审评资格，encaleret已提交新药申请并计划2027年初上市，infigratinib三期Propel 3试验数据已在《新英格兰医学杂志》发表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650926042","title":"BridgeBio Pharma(BBIO)盘前大涨13.62% 传私募资本KKR等拟投资10亿美元加速创新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2650926042","media":"金吾财讯","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650926042?lang=zh_cn&edition=full","pubTime":"2026-07-09 19:20","pubTimestamp":1783596018,"startTime":"0","endTime":"0","summary":"金吾财讯 | BridgeBio Pharma(BBIO)盘前大涨13.62%，最新报89.00美元。消息面上，近日市场媒体爆料称，私募资本KKR与Sixth Street Partners已同意向生物科技公司BridgeBio Pharma提供10亿美元融资，通过发行优先股完成。该笔融资将帮助BridgeBio加速推出针对遗传病的创新药。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302388","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1574","BK4139","LU1201861249.SGD","BK4135","IE00BGHQF748.EUR","LU1791807156.HKD","LU0314104364.USD","06978","IBBQ","LU1935043536.SGD","BK4588","LU1935043023.USD","PSP","IE00B64PRP62.GBP","LU1935042215.USD","LU0980610538.SGD","BK1161","LBO","LU0130102774.USD","IPOS","BK4585","MEDX","LU0106831901.USD","LU1935042991.SGD","LU1668664300.SGD","LU1935042488.USD","BK4505","IE00B3QW5Z07.USD","BBIO","KKR","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181643931","title":"异动解读｜BridgeBio Pharma盘前上涨5.31%，10亿美元融资助力三款罕见病新药上市冲刺","url":"https://stock-news.laohu8.com/highlight/detail?id=1181643931","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181643931?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:11","pubTimestamp":1783584706,"startTime":"0","endTime":"0","summary":"7月9日，BridgeBio Pharma盘前上涨5.31%，报82.10美元/股，成交额7.48万美元。消息面上，公司近期完成10亿美元可转换优先股融资，由Sixth Street领投8亿美元，资金将用于三款罕见病核心管线的商业化推进：BBP-418、encaleret及infigratinib。其中infigratinib三期Propel 3试验数据已于6月底在《新英格兰医学杂志》正式发表，BBP-418已向FDA提交新药申请。公司正从研发阶段向多产品商业化阶段加速转型，融资条款中初始转换价较30日均价溢价100%，显示投资方对公司估值的认可。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160347922","title":"BridgeBio宣布口服英菲格拉替尼治疗儿童软骨发育不全的3期Propel 3试验结果发表于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1160347922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160347922?lang=zh_cn&edition=full","pubTime":"2026-06-29 04:01","pubTimestamp":1782676873,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 宣布，其口服英菲格拉替尼用于治疗儿童软骨发育不全患者的3期Propel临床试验数据，已在《新英格兰医学杂志》上正式发表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","BBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128463808","title":"异动解读｜BridgeBio Pharma盘中上涨5.04%，报69.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1128463808","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128463808?lang=zh_cn&edition=full","pubTime":"2026-06-23 02:15","pubTimestamp":1782152115,"startTime":"0","endTime":"0","summary":"6月23日，BridgeBio Pharma盘中上涨5.04%，报69.55美元/股，成交额6731.04万美元。BridgeBio Pharma所在的生物科技行业中，个股表现分化，其中Apogee Therapeutics涨46.72%，艾伯维公司涨6.92%，吉利德科学涨0.95%，再生元制药公司跌0.22%，Moderna跌5.8%。BridgeBio Pharma是一家处于商业阶段的生物制药公司，旨在发现、创造、测试和提供具有变革性的药物，以治疗具有明确遗传驱动因素的遗传性疾病和癌症患者。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194973640","title":"BridgeBio Pharma, Inc. 将于2026年夏季启动Encaleret治疗慢性甲状旁腺功能减退症的3期Reclaim-HP研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1194973640","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194973640?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:32","pubTimestamp":1778585567,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 宣布，计划于2026年夏季启动其候选药物Encaleret用于治疗慢性甲状旁腺功能减退症（HP）的3期关键性临床试验，该研究代号为Reclaim-HP。\n这项研究旨在评估Encaleret在慢性甲状旁腺功能减退症患者中的疗效与安全性，标志着该药物研发进程中的一个重要里程碑。公司此举旨在进一步验证该疗法的潜力，并为未来的监管申请奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBIO","BK4505","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187872314","title":"BridgeBio Pharma 公司新药 Encaleret 有望获优先审评，美国市场预计2027年初上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1187872314","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187872314?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:31","pubTimestamp":1778585475,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 旗下新药 Encaleret 的上市申请或将有资格获得美国食品药品监督管理局的优先审评资格。若进展顺利，该药物在美国市场的商业化推出时间预计将定于2027年初。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BBIO","BK4588","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177534862","title":"Acoramidis持续展现对ATTR-CM的疾病修饰效应，降低血清TTR变异率并减少门诊心衰恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1177534862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177534862?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:31","pubTimestamp":1778506290,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma旗下药物Acoramidis在治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）方面，持续显示出其疾病修饰作用。最新数据表明，该药物能有效降低血清转甲状腺素蛋白（TTR）的变异水平，同时显著减少了门诊患者心力衰竭恶化的发生频率。这一进展进一步印证了Acoramidis在改变疾病进程方面的潜力，为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BBIO","BK4588","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151422750","title":"Beyonttra™（Acoramidis）成为巴西首个获批治疗ATTR-CM的近完全TTR稳定剂（≥90%）","url":"https://stock-news.laohu8.com/highlight/detail?id=1151422750","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151422750?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:31","pubTimestamp":1778067076,"startTime":"0","endTime":"0","summary":"巴西国家卫生监督局（Anvisa）已正式批准Beyonttra™（Acoramidis）上市，该药物是全球首款近完全转甲状腺素蛋白（TTR）稳定剂，其稳定效率达到90%及以上，用于治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）。这一批准标志着巴西ATTR-CM患者迎来了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BBIO","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bridgebio.com","stockEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.028},{"period":"3month","weight":-0.1842},{"period":"6month","weight":-0.135},{"period":"1year","weight":0.2064},{"period":"ytd","weight":-0.132}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日在特拉华州成立。该公司是一家处于商业阶段的生物制药公司，旨在发现、创造、测试和提供具有变革性的药物，以治疗具有明确遗传驱动因素的遗传性疾病和癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.043127},{"month":2,"riseRate":0.428571,"avgChangeRate":0.009556},{"month":3,"riseRate":0.428571,"avgChangeRate":0.078186},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.068249},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.038027},{"month":6,"riseRate":0.857143,"avgChangeRate":0.14482},{"month":7,"riseRate":0.625,"avgChangeRate":0.126463},{"month":8,"riseRate":0.625,"avgChangeRate":0.028555},{"month":9,"riseRate":0.25,"avgChangeRate":-0.06233},{"month":10,"riseRate":0.75,"avgChangeRate":0.037601},{"month":11,"riseRate":0.714286,"avgChangeRate":0.102784},{"month":12,"riseRate":0.714286,"avgChangeRate":0.047197}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}